Loading
Latest filing published 11 Mar 2026 for 비보존 제약, €19k. Read the official filing
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
장부환, listed as chief executive, appears in our data through filings on 비보존 제약 shares, published by DART (FSS). In total, 4 filings cover trades dated from 31 January 2024 to 5 March 2026.
No open-market sale appears; the market trades are 4 purchases worth €19k. The amount is not disclosed for 3 filings. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2026 alone, the filings show 2 purchases and no sales.
On 1 out of 3 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
Most recently, on 11 March 2026, the filings show an open-market purchase worth €19k in 비보존 제약. Filings reach the DART (FSS) feed a median of 5 days after the trade. That lag is the time during which only the insider knows about the trade. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations